VEGFA and diabetes mellitus: Viggiano et al. [42], who investigated the morphologic modifications of the choriocapillaris using OCTA in patients with type 1 MNV before and after the introduction of intravitreal anti-VEGF agents, observed that patients with diabetes had significantly lower choriocapillaris perfusion even before treatment compared to patients without diabetes, and this did not significantly change after treatment.